Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: Abemaciclib;   Drug: Nivolumab;   Procedure: Tumor biopsy;   Procedure: Peripheral blood;   Other: EORTC QLQ-30
Sponsors:   Washington University School of Medicine;   Eli Lilly and Company
Not yet recruiting

https://ift.tt/2NaJPAM